Skip to main content

Table 6 Risks of death and hospitalisations: subgroup analysis in patients with renal impairment

From: Clinical effects, cardiovascular and renal outcomes associated with rapid-acting insulin analogs among individuals with type 2 diabetes: a nation-wide observational cohort study

Event Aspart vs lispro Glulisine vs lispro Glulisine vs aspart
Total Mortality 0.97 [0.61, 1.54] 0.56 [0.21, 1.50] 0.58 [0.24, 1.40]
CHD 1.05 [0.70, 1.60] 0.96 [0.51, 1.81] 0.91 [0.55, 1.50]
Fatal CHD 1.17 [0.79, 1.74] 1.04 [0.50, 2.16] 0.89 [0.47, 1.67]
CVD 1.12 [0.76, 1.66] 1.00 [0.56, 1.80] 0.89 [0.56, 1.41]
Fatal CVD 1.47 [0.67, 3.26] 0.68 [0.12, 3.84] 0.46 [0.10, 2.19]
Stroke 1.32 [0.50, 3.51] 0.64 [0.12, 3.34] 0.49 [0.12, 2.06]
Heart Failure 1.03 [0.65, 1.64] 0.65 [0.28, 1.52] 0.63 [0.30, 1.31]
Kidney Failure 1.20 [0.76, 1.88] 0.98 [0.47, 2.03] 0.82 [0.45, 1.48]
Hypoglycaemia 1.46 [0.45, 4.72] 1.33 [0.22, 8.20] 0.91 [0.22, 3.82]
Hyperglycaemia 3.32 [0.46, 24.19] N/A N/A
  1. Weighted Cox proportional hazards analysis. Estimated hazard ratios with 95% confidence intervals. * p-value <0.05